AgeX Therapeutics, Inc.

As of May 8, 2025, AgeX Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade due to extremely low return on equity and negative financial ratios, significantly underperforming compared to its peers and the S&P 500.

As of June 13, 2025, AgeX Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and moving averages, though caution is warranted due to mixed signals from Dow Theory and Bollinger Bands.

As of March 2022, the management team of AgeX Therapeutics, Inc. includes Dr. Gregory Bailey (Independent Chairman), Dr. Michael West (CEO and Founder), and Independent Directors Dr. Annalisa Jenkins and Dr. Michael May.

AgeX Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for human aging, categorized as a micro-cap with a market cap of approximately $51.93 million. As of March 2025, it reported a net profit loss of $5 million and has no dividend yield.

As of Jun 18, AgeX Therapeutics, Inc. has a market capitalization of 51.93 million, with net sales of 0.07 million and a net profit of -7.70 million over the last four quarters. The company reported shareholder's funds of 0.64 million and total assets of 6.72 million as of Dec 24.